Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus

Pharmacogenomics

Volumn 11, Issue 11, 2010, Pages 1517-1523

  Swen, Jesse J ^a   Wessels, Judith A M ^a   Krabben, Annemarie ^a   Assendelft, Willem J J ^a   Guchelaar, Henk Jan ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CYP2C9; glibenclamide; gliclazide; glimepiride; pharmacogenetics; sulfonylureas; tolbutamide; Type 2 diabetes mellitus

Indexed keywords

CYTOCHROME P450 2C9; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; METFORMIN; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE;

ADULT; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG METABOLISM; ELECTRONIC MEDICAL RECORD; ENZYME POLYMORPHISM; FEMALE; GENOTYPE; HETEROZYGOTE DETECTION; HOMOZYGOSITY; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPTIMAL DRUG DOSE; PRESCRIPTION; PRIMARY MEDICAL CARE; SEX DIFFERENCE; TREATMENT DURATION;

ALLELES; ARYL HYDROCARBON HYDROXYLASES; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG PRESCRIPTIONS; FEMALE; GENETIC TESTING; GENOTYPE; HUMANS; HYPOGLYCEMIC AGENTS; KAPLAN-MEIER ESTIMATE; MALE; MEDICAL RECORDS; MIDDLE AGED; NETHERLANDS; POLYMORPHISM, GENETIC; PRIMARY HEALTH CARE; RETROSPECTIVE STUDIES; SALIVA; SULFONYLUREA COMPOUNDS; TIME FACTORS;

EID: 78649710075     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.121     Document Type: Article

References (18)

1. Krentz AJ, Bailey CJ: Oral antidiabetic agents: current role in Type 2 diabetes mellitus. Drugs 65(3), 385-411 (2005).
2. Jennings AM, Wilson RM, Ward JD: Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents. Diabetes Care 12(3), 203-208 (1989).
3. Kirchheiner J, Brockmoller J, Meineke I et al.: Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin. Pharmacol. Ther. 71(4), 286-296 (2002). (Pubitemid 34311458)
4. Yin OQ, Tomlinson B, Chow MS: CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects. Clin. Pharmacol. Ther. 78(4), 370-377 (2005).
5. Shon JH, Yoon YR, Kim KA et al.: Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. Pharmacogenetics 12(2), 111-119 (2002).
6. Kirchheiner J, Bauer S, Meineke I et al.: Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics 12(2), 101-109 (2002). (Pubitemid 34298914)
7. Wang R, Chen K, Wen SY, Li J, Wang SQ: Pharmacokinetics of glimepiride and cytochrome P450 2C9 genetic polymorphisms. Clin. Pharmacol. Ther. 78(1), 90-92 (2005).
8. Suzuki K, Yanagawa T, Shibasaki T, Kaniwa N, Hasegawa R, Tohkin M: Effect of CYP2C9 genetic polymorphisms on the effcacy and pharmacokinetics of glimepiride in subjects with Type 2 diabetes. Diabetes Res. Clin. Pract. 72(2), 148-154 (2006).
9. Zhang Y, Si D, Chen X et al.: Infuence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects. Br. J. Clin. Pharmacol. 64(1), 67-74 (2007).
10. Ragia G, Petridis I, Tavridou A, Christakidis D, Manolopoulos VG: Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. Pharmacogenomics 10(11), 1781-1787 (2009).
11. Holstein A, Plaschke A, Ptak M et al.: Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br. J. Clin. Pharmacol. 60(1), 103-106 (2005).
12. Becker ML, Visser LE, Trienekens PH, Hofman A, Van Schaik RH, Stricker BH: Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in Type 2 diabetes mellitus. Clin. Pharmacol. Ther. 83(2), 288-292 (2008).
13. Zhou K, Donnelly L, Burch L et al.: Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in Type 2 diabetes: a go-DARTS study. Clin. Pharmacol. Ther. 87(1), 52-56 (2009).
14. Rutten GEHM, De Grauw WJC, Nijpels G et al.: NHG-Standard diabetes mellitus Type 2. Huisarts Wet. 49(3), 137-152 (2006).
15. Van Loenen AC: Farmacotherapeutisch Kompas 2010. Van Loenen AC, Sitsen JMA (Eds). College voor zorgverzekeringen, Diemen, The Netherlands (2010).
16. Van den Berg MJ, de Bakker DH, Spreeuwenberg P et al.: Labour intensity of guidelines may have a greater effect on adherence than GPs' workload. BMC Fam. Pract. 10, 74 (2009).
17. Lin Y, Sun Z: Current views on Type 2 diabetes. J. Endocrinol. 204(1), 1-11 (2009).
18. Ridderstrale M, Groop L: Genetic dissection of Type 2 diabetes. Mol. Cell Endocrinol. 297(1-2), 10-17 (2009).